Nutra Pharma Corp., a biotechnology company, has announced that its subsidiary, ReceptoPharm, has published positive results from its recent study on the use of cobratoxin, for the relief of pain.
ReceptoPharm is currently studying the effectiveness of Cobra Venom and Cobratoxin as treatments for Multiple Sclerosis, HIV, Adrenomyeloneuropathy (AMN), and Rabies.
"There are many historical reports of venoms being used in association with pain relief," explained Dr Paul Reid, CEO of ReceptoPharm. "The purpose of this study was to examine the pain relieving effects of cobratoxin on laboratory mice. The results suggest that cobratoxin is effective in the relief of pain and might actually be a useful substitute for morphine," he said.
The study was published in the April 2006 issue of Acta Pharmacologica Sinica, an international monthly publication and the official journal of the Chinese Pharmacological Society and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
"We are enthusiastic about the results of this recent study," commented Rik J. Deitsch, chairman and CEO of Nutra Pharma Corporation. "Results like these drive ReceptoPharm's continued research and clinical studies. We hope to continue publishing positive results, as we begin our phase II trials in diseases that lack treatment options, like Multiple Sclerosis and AMN," he added.
ReceptoPharm recently announced their approval by the British Medicines and Healthcare products Regulatory Agency to begin phase II human trials for the treatment of AMN.